US › Healthcare

Adial Pharmaceuticals Inc (ADIL)

US · Healthcare · Biotechnology

$3.49+11.15%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-52.0M

EPS

$-11.25

EPS estimate

$-0.91

EPS came in at -11.25 against a street estimate of -0.91 — a miss of 1136.3%.

Key statistics

Market cap

$8.6M

Forward P/E

0.0

P/B

3.52

Book value

$-14.62

EPS (TTM)

$-20.65

52-week high

$9.90

52-week low

$1.31

50-day MA

$4.89

200-day MA

$3.37

Beta

1.50

Analyst view

Analysts rate Adial Pharmaceuticals Inc a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $8.33.

Shareholding

Insiders

7.08%

Institutions

29.85%

Largest institutional holders

Fund	Stake
Jane Street Group LLC	1.22%
Citadel Advisors Llc	1.13%
StoneX Group Inc	0.75%
UBS Group AG	0.73%
Geode Capital Management, LLC	0.47%
China Universal Asset Mgmt Co.Ltd	0.30%
Vanguard Fiduciary Trust Co	0.22%
Vanguard Capital Management, LLC	0.22%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Adial Pharmaceuticals Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.